Neurocrine Biosciences (NBIX) Misses Q1 EPS by 7c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $156.22 -0.22%
EPS Growth %: -12.4%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
ANAB, ANIX, MNY, More
EPS Growth %: -12.4%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $0.70, $0.07 worse than the analyst estimate of $0.77. Revenue for the quarter came in at $572.6 million versus the consensus estimate of $593.71 million.
GUIDANCE
INGREZZA Net Product Sales between $2.5-2.6 billion
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corning (GLW) files for up to $2B offering of common shares
- Goldman, BofA vie to manage Anthropic employee wealth post-IPO - report
- Roblox announces standalone apps, browser play, and creator wallet
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
